Dulaglutide · source year
6 selected, source-linked Dulaglutide records carrying a 2014 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
2 represented types.
6 distinct public records.
Cited chronology
Regulatory
DailyMed lists Structured Product Labeling version 5 for the reviewed Dulaglutide label family with a published date of 2014-10-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01524770 at 2026-07-30T21:54:46.539Z. Its registry update date was 2014-10-22, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01432938 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01436201 at 2026-07-30T21:54:46.550Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 4 for the reviewed Dulaglutide label family with a published date of 2014-10-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for BLA 125469 with status AP dated 2014-09-18, and names dulaglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗